An excess of carbohydrates may be to blame for higher risk of premature deaths, not fats.
Lower incidence of major coronary events for patients with atherosclerotic vascular disease receiving intensive statins is linked with use of anacetrapib.
Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles.
Incidence for undiagnosed atrial fibrillation high from insertable cardiac monitors.
In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.
Supplemental oxygen therapy does not decrease the risk for 1-year all-cause mortality in patients with suspected myocardial infarction.
Despite more major bleeding events, rivaroxaban plus aspirin therapy had a greater cardiovascular benefit in patients with stable atherosclerotic vascular disease vs monotherapy.
In high-risk patients with atherosclerotic disease, canakinumab may help reduce the incidence of cardiovascular events.
The Cardiology Advisor Articles
- Continuous Furosemide Infusion Superior to Bolus Furosemide in Heart Failure
- ACC/AHA Release 2017 Quality Measures for STEMI/NSTEMI Management
- Role of Coffee Consumption in Heart Failure, Stroke Outcomes
- Atrial Fibrillation Survival Better With Cardiac Surgery, Cox-Maze IV
- Borderline Pulmonary Hypertension Commonly Found During Right Heart Catheterization
- Heart Failure Related to Methamphetamine Use: Possible New Epidemic?
- Cardiac Surgery: Restrictive vs Liberal Threshold for Red-Cell Transfusion
- High-Sensitivity Cardiac Troponin I Threshold Identifies Patients at Low Risk for MI, Death
- Hospital Readmissions Reduction Program Decreases Heart Failure Readmissions
- Canakinumab May Lower Lung Cancer Incidence in Patients With Atherosclerosis